Montasser, M., Hassanin, E., Abdelmohsen, S., Zamzam, M. (2018). Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital. Suez Canal University Medical Journal, 21(1), 40-49. doi: 10.21608/scumj.2018.43356
Manar Montasser; Ehab M Hassanin; Soheir E Abdelmohsen; Maha L Zamzam. "Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital". Suez Canal University Medical Journal, 21, 1, 2018, 40-49. doi: 10.21608/scumj.2018.43356
Montasser, M., Hassanin, E., Abdelmohsen, S., Zamzam, M. (2018). 'Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital', Suez Canal University Medical Journal, 21(1), pp. 40-49. doi: 10.21608/scumj.2018.43356
Montasser, M., Hassanin, E., Abdelmohsen, S., Zamzam, M. Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital. Suez Canal University Medical Journal, 2018; 21(1): 40-49. doi: 10.21608/scumj.2018.43356
Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Suez Canal University, Egypt
Abstract
Background:There are limited data in the literature comparing the efficacy of aromatase inhibitors in postmenopausal hormonal receptor positive early breast cancer patients. Aim: To compare the efficacy of letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients. Patients and Methods: A retrospective study with a mean follow-up period of 64 months (about 5 years) for 74 files of early invasive postmenopausal breast cancer hormonal receptor positive patients; 39 received letrozole and 35 received anastrozole, considering TTP as primary end point, and OS as second end points. Results:Letrozole is not superior to anastrozole during the first 55 months of treatment (80% PFS at 5th year), and 80% OS benefit at 6th year.. Overweight patients had better (90% PFS at 5th year) than obese patients (60% PFS at 5th year). Conclusion: Letrozole is not superior to anastrozole in efficacy in early invasive hormonal receptor positive breast cancer postmenopausal patients during the first 5 years of treatment; however, Letrozole 2nd line after tamoxifen is superior to anastrozole 2nd line after tamoxifen in treating obese patients with early invasive hormone receptor positive breast cancer.
View on SCiNiTO
Top